Related by context. All words. (Click for frequent words.) 84 Scandinavian Cardiac Outcomes 63 Trandolapril 62 multicenter Phase II 61 prospective randomized multicenter 60 CARE HF 60 Multicenter 60 multicenter phase 60 multicenter randomized controlled 60 RE LY 60 ExTRACT TIMI 59 Cholesterol Levels SPARCL 59 Heart Failure Trial 59 Edge STudy 59 Rosuvastatin 59 Cardiovascular Outcomes 59 Aggressive Reduction 59 ADVANCE PD 59 phase IIb trial 58 phase IIIb 58 Val HeFT 58 Phase IIIb study 58 prospective observational 58 Intervention Effectiveness 58 phase IIb clinical 58 RE LY trial 58 Phase Ib clinical 58 multicenter Phase III 57 CHAMPION PCI 57 PARTNER Trial 57 subanalysis 57 EVEREST II 57 BRIM3 57 PERSEUS 57 Phase Ib II 57 DU #b 57 Intervention Trial GAIT 57 multicenter placebo controlled 57 REALITY Trial 57 phase IIa clinical 57 ASTEROID 57 phase IIa 57 randomized multicenter 57 double blinded placebo 57 RE LY ® 57 Platelet Inhibition 57 Phase IIIb 57 Randomized Study 57 Clinical Antipsychotic Trials 57 Candesartan 57 RIO Lipids 57 ONTARGET 57 prospective randomized placebo 57 MEND CABG 57 multicenter prospective 57 Valsartan 56 PROactive study 56 Phase III placebo controlled 56 placebo controlled Phase III 56 prospective multicenter 56 HYVET 56 PROactive Study 56 multicentre randomized controlled 56 active comparator 56 GOUT 56 MERLIN TIMI 56 randomized Phase IIb 56 elotuzumab 56 Acute Decompensated Heart Failure 56 Screening Trial 56 SPIRIT FIRST 56 ABSORB trial 56 MADIT CRT 56 ENESTnd 56 olaparib 56 CLARITY TIMI 56 TRITON TIMI 55 Lipid Lowering Treatment 55 multicentre 55 multicentre randomized 55 clazosentan 55 rosuvastatin Crestor 55 SORT OUT III 55 zotarolimus eluting stent 55 candesartan cilexetil 55 Stenting Trial CREST 55 Evaluation WISE 55 rosuvastatin 55 AIM HIGH 55 TG MV 55 phase IIb 55 double blinded randomized 55 Phase 1b clinical 55 HCV RESPOND 2 55 randomized Phase III 55 CHARISMA trial 55 CLL8 55 fluvastatin 55 Digital Mammographic Imaging 55 TRA 2P 55 Carotid Revascularization Endarterectomy vs. 55 Randomized Clinical Trial 55 randomized multicenter trial 55 Ambulatory Blood Pressure 55 ATACAND 55 SPARCL 55 Val MARC 55 CRESTOR #mg 55 dyslipidaemia 55 EURIDIS 55 ZACTIMA 55 pertuzumab 55 blinded randomized placebo controlled 55 Phase 1b trial 55 Intervention Effectiveness CATIE 54 Subgroup analysis 54 Observational Study 54 Phase IIIb clinical 54 TAXUS V 54 multicenter randomized 54 International Verapamil SR 54 EchoCRT 54 randomized blinded 54 candesartan 54 Communities ARIC study 54 CYPHER Stent 54 multicenter multinational 54 Multicenter Study 54 riociguat 54 hypercholesterolaemia 54 STRIDE PD 54 genomewide association study 54 ILLUSTRATE 54 placebo controlled clinical 54 HCV SPRINT 54 ENDEAVOR IV 54 multicenter clinical 54 multicenter randomized placebo controlled 54 Prostate Lung Colorectal 54 prospective multicentre 54 glitazone 54 Bucindolol 54 CIMZIA TM certolizumab pegol 54 prospective nonrandomized 54 Myocardial Infarction 54 Phase III randomized 54 multicenter randomized clinical 54 Aliskiren 54 BARI 2D 54 NATRECOR R 54 multicentre randomized double 54 unfractionated heparin UFH 54 Randomized controlled 54 Patency 54 LHRH receptor positive 54 pharmacokinetics PK 54 TAXUS ATLAS 54 landmark ATHENA trial 54 HeFT 54 Randomized Phase 54 TAXUS IV 54 ritonavir boosted 53 NSABP B 53 dose escalation clinical 53 ECASS 53 GISSI HF 53 RIO Diabetes 53 randomized controlled clinical trials 53 TAXUS VI 53 ORMD 53 relapsed MM 53 Denufosol 53 Prospective Randomized 53 anti arrhythmic drug 53 EMPHASIS HF trial 53 metastatic HRPC 53 Phase 2a clinical 53 Left Ventricular Dysfunction 53 BRIM2 53 Intervention Trial 53 Prospective Randomized Trial 53 thorough QT 53 Tocilizumab 53 pharmacokinetic PK study 53 MADIT II 53 Controlled Trial 53 NATRECOR ® 53 Enzastaurin 53 BR.# 53 fosbretabulin 53 randomized controlled clinical 53 Cardiovascular Risk 53 Complications Trial 53 Multiethnic Study 53 phase IIb study 53 Xelox 53 Betaferon ® 53 Phase III metastatic melanoma 53 Phase III VISTA 53 multicentre study 53 CURRENT OASIS 7 53 irbesartan 53 thiazolidinedione TZD 53 telmisartan 53 ALLHAT 53 sorafenib Nexavar 53 trials RCTs 53 PCI ExTRACT TIMI 53 LUX Lung 53 multicenter 53 EINSTEIN DVT 53 phase Ib 53 Telmisartan 53 Antihypertensive 53 HORIZONS AMI 53 Ovarian Cancer Screening 53 Diabetologia 53 ANCHOR trial 53 prospective randomized controlled 52 placebo controlled randomized 52 multicenter randomized double 52 tolvaptan 52 Ranolazine 52 randomized multicenter Phase III 52 NO# [002] 52 everolimus eluting stent 52 randomized multicentre 52 Endovascular Valve Edge 52 AVERROES 52 Perindopril 52 Screening Trial DMIST 52 longitudinal cohort study 52 eprotirome 52 SCD HeFT 52 Lp PLA2 52 Venous Thromboembolism 52 ToGA 52 Pooled Analysis 52 NICE SUGAR 52 TAXUS Express Stent 52 glycated hemoglobin HbA1c 52 Multicenter AIDS 52 Atacand 52 noninferior 52 PICSO ® 52 atrasentan 52 EmbraceAC 52 MADIT CRT trial 52 Randomised 52 IMPACT DCM 52 dose escalation Phase 52 RECORD1 52 Sorafenib HCC Assessment 52 Atherosclerosis MESA 52 TMC# C# 52 valsartan 52 prospective multicenter randomized 52 teriflunomide 52 VADT 52 hypertensive patients 52 Acute Coronary Syndrome 52 ENDEAVOR II 52 number NCT# ClinicalTrials.gov 52 ACTEMRA TM 52 TIMI Study Group 52 Randomized Evaluation 52 basal bolus regimen 52 LEXIVA r 52 lipid lowering drugs 52 nonrandomized 52 BOLDER II 52 randomized clinical 52 Lancet Oncology journal 52 tirofiban 52 atorvastatin Lipitor 52 ACCORD Lipid 52 Stent Thrombosis 52 factor Xa inhibitor 52 PRoFESS 52 PFO migraine 52 Clinical Outcomes Utilizing Revascularization 52 CAPRIE 52 CALERIE 52 Multi Ethnic Study 52 placebo controlled Phase 52 landmark ATHENA 52 vildagliptin 52 hypercholesterolemia 52 SPIRIT IV 52 TRANSFORMS 51 multicenter Phase 51 HIV HCV coinfected 51 Acute Ischemic Stroke 51 multicentre prospective 51 Phase 1a clinical 51 ezetimibe Zetia 51 Myocardial Ischemia 51 ARCOXIA 51 Phase 2b clinical 51 Phase #/#a 51 randomized blinded placebo 51 Ovarian PLCO Cancer 51 inhibitor RG# 51 Dr. Kandzari 51 SYNTAX trial 51 Aggressive Drug Evaluation 51 AIR2 Trial 51 AVOREN 51 clinical pharmacology studies 51 Pulmonary Arterial Hypertension 51 Septic Shock 51 retrospective cohort 51 acute coronary syndromes ACS 51 serum leptin 51 APPRAISE 51 Phase 2b study 51 pharmacokinetic PK 51 RSD# oral 51 observational cohort study 51 metaanalysis 51 PLCO 51 Acute Coronary Syndromes 51 Oxidized LDL 51 phase III ACCLAIM 51 metreleptin 51 viral kinetic 51 Phase IIa trial 51 COU AA 51 sunitinib malate 51 Systolic Hypertension 51 ARBITER 6 51 evaluating mipomersen 51 nondiabetic patients 51 NCCTG N# 51 antiretroviral naïve 51 registrational Phase 51 Nesiritide 51 abacavir Ziagen 51 chronic thromboembolic pulmonary 51 Diabetic Nephropathy 51 odanacatib 51 multicenter trials 51 ORACLE MS 51 Hypertension ASH 51 Hematological 51 STICH trial 51 ASCEND HF 51 Phase Ia 51 HORIZONS AMI trial 51 paricalcitol 51 placebo controlled dose escalation 51 pivotal bioequivalence 51 SYNTAX 51 Celebrex celecoxib 51 tolerability pharmacokinetics 51 Prostate Cancer Prevention 51 Raloxifene Evaluation MORE 51 lipid lowering agents 51 ANDROMEDA 51 vicriviroc 51 randomized Phase 2b 51 AA Amyloidosis 51 ACE Inhibitor 50 risperidone Risperdal 50 morphometric vertebral fractures 50 Meta Analysis 50 Pharmacokinetic studies 50 efavirenz EFV 50 fasting serum 50 eosinophilic asthma 50 CALGB 50 label multicenter randomized 50 randomized trials 50 Degarelix 50 BR.# study 50 LCP AtorFen 50 myocardial uptake 50 II Clinical Trial 50 controlled multicenter 50 ACUITY trial 50 ezetimibe simvastatin 50 Fulvestrant 50 Cardiovascular Pharmacology 50 MSI #F 50 ACRIN 50 Therapeutic Advances 50 Cardiac Allograft Rejection 50 rFVIIa 50 Prospective Multicenter 50 Carotid Stenting 50 label multicenter 50 prospective observational cohort 50 Rheumatoid Arthritis RA 50 multicenter study 50 desvenlafaxine succinate 50 UKPDS 50 ABSORB clinical 50 confirmatory clinical 50 Phase Ib study 50 antihypertensive therapy 50 patientswith 50 ACCOMPLISH 50 Phase IIB 50 Health Initiative WHI 50 Phase Ib 50 somatostatin analog 50 substudy 50 Myocardial Infarction Study 50 macrovascular disease 50 blind randomized placebo 50 blind randomized controlled 50 PREVENT IV 50 Lp PLA 2 50 sirolimus eluting 50 dyslipidemia 50 Subgroup Analysis 50 CUSTOM III 50 EDEMA3 50 Diabetes ACCORD 50 ug dose 50 Aortic Stenosis 50 #mg BID [001] 50 Tiotropium 50 Arch Neurol 50 CAMMS# 50 AIR CF2 50 BCIRG 50 meta analysis 50 GRAVITAS trial 50 elevated LDL cholesterol 50 Dialysis Outcomes 50 ACOSOG Z# 50 salmeterol fluticasone 50 Phase 1a 50 undergone radical prostatectomy 50 dose escalation trial 50 J Am Coll 50 Non Alcoholic Steatohepatitis 50 visceral metastases 50 oral antidiabetic medication 50 Phase 2a trial 50 Phase 1b 50 pharmacodynamic effects 50 Randomised Study 50 XIENCE V PROMUS Stent 49 atherogenic dyslipidemia 49 meta regression 49 Study AREDS 49 liver transplant recipients 49 beta blocker therapy 49 β blockers 49 non cirrhotic portal 49 Gynecologic Oncology Group 49 serum lipid levels 49 CARDIA study 49 Angiographic 49 J Nutr 49 OLYMPIA registry 49 Acute Myocardial Infarction 49 PROVE IT 49 ASPIRE HIGHER 49 REVLIMID lenalidomide 49 Feasibility Trial 49 PROSTVAC TM 49 polyarticular 49 CONQUER OB 49 stage IIIb IV 49 Dyslipidemia 49 Multicentre 49 mITT population 49 ascending dose 49 oral ridaforolimus 49 everolimus eluting stents 49 randomized clinical trials 49 ROCKET AF 49 CLARITY study 49 randomized placebo controlled 49 Atherosclerosis Risk 49 NSTE ACS 49 blind multicenter 49 PRECiSE 49 HIV seroconversion 49 STEP BD 49 MAGE A3 ASCI 49 MGd 49 recurrent glioblastoma multiforme 49 retrospective cohort study 49 muraglitazar 49 elevated fasting glucose 49 onset diabetes mellitus 49 CANCIDAS 49 ENDEAVOR 49 randomized crossover 49 statins cholesterol lowering 49 CARDIA 49 Framingham Offspring Study 49 treatment naive genotype 49 treatment naïve genotype 49 phase 2a 49 dabigatran etexilate 49 ARB telmisartan 49 Coronary artery calcification 49 SPIRIT III 49 genetic variants associated 49 PRIMO CABG2 49 TMC# r 49 coinfected patients 49 DAPT 49 DMIST 49 doxorubicin docetaxel 49 INTERHEART study 49 RAPAFLO R 49 REVIVE Diabetes 49 prospective randomized 49 Surgical Treatment 49 XZK 49 invasive candidiasis 49 QUASAR validation study 49 pravastatin therapy 49 diabetes hyperlipidemia 49 acute coronary syndrome 49 Coronary Artery Calcium 49 Stage IIIb 49 PROSTVAC ® 49 pegylated liposomal doxorubicin 49 Women Ischemia Syndrome 49 Celecoxib APC trial 49 bazedoxifene conjugated estrogens 49 DAPT Study 49 canakinumab 49 pharmacodynamics PD 49 beta carotene supplementation 49 mycophenolate mofetil 49 ADAGIO study 49 HPTN 49 gadobutrol 49 Perforomist Inhalation Solution 49 See CLINICAL PHARMACOLOGY 49 Sipuleucel T 49 serum uric acid 49 Trial PCPT 49 Phase IIa clinical 49 APTIVUS 49 refractory CLL 49 aspirin clopidogrel 49 Phase Ib IIa clinical 49 Phase 2b 49 Study HERS 49 anacetrapib 49 Blood Pressure Monitoring 48 Practice Patterns 48 RG# ITMN 48 Corus CAD 48 ximelagatran 48 PRTX 48 cardiovascular morbidity 48 CYPHER R Sirolimus eluting 48 pharmacodynamics 48 NCT# ClinicalTrials.gov 48 Hypertriglyceridemia 48 multicentric 48 dysglycemia 48 #-# Full Text 48 Arteriosclerosis Thrombosis 48 Benign Prostatic Hyperplasia 48 darunavir r 48 Percutaneous Coronary Intervention 48 eptifibatide 48 CUSTOM II 48 oral rivaroxaban 48 Neuroepidemiology 48 journal Ophthalmology 48 REVIVE TA 48 null responder HCV 48 CombAT 48 Thrombolysis 48 BOLDER 48 Thromboembolism 48 pharmacokinetic studies 48 uncontrolled hypertension 48 sunitinib 48 ENGAGE AF TIMI 48 NHANES III 48 randomized controlled 48 recurrent endometrial cancer 48 stable angina 48 EQUIP OB 48 placebo controlled clinical trials 48 PRE SURGE 48 Chronic Heart Failure 48 prostate cancer CaP 48 blinded placebo controlled 48 AIR CF1 48 total cholesterol triglycerides 48 skin sterol 48 ACCLAIM 48 prucalopride 48 goserelin 48 Randomized trials 48 Phase IIa 48 recurrent malignant glioma 48 GISSI 48 ABSSSI 48 prospective multicenter study 48 AVADO 48 psoriatic arthritis PsA 48 #:#-# [031] 48 VITAL Trial 48 ASCOT LLA 48 Diabetes Interventions 48 Hospital Acquired Pneumonia 48 achieved sustained virological 48 homozygous familial hypercholesterolemia 48 atherothrombosis 48 antihypertensive drugs 48 losartan 48 CATIE AD 48 Phase IIb clinical 48 Cardiovascular Events 48 ConclusionThis 48 cinacalcet 48 HMG CoA reductase inhibitors 48 NSABP 48 Hematology Meeting 48 BENICAR HCT 48 deferiprone 48 prospective cohort 48 glitazones 48 virologic response 48 Relapsing Remitting Multiple Sclerosis 48 boosted protease inhibitor 48 Acute Myocardial 48 APPROVe 48 journal Circulation Cardiovascular 48 Psychiatry #:#-# [003] 48 ALLEGRO 48 mg BID dose 48 normotensive 48 lipid lowering therapy 48 Meta analyzes 48 Young Adults CARDIA 48 pain palliation 48 SABCS 48 masked placebo controlled 48 oral deforolimus 48 Fractional Flow Reserve 48 relapsed myeloma 48 superficial bladder cancer 48 angiotensin receptor blockers ARBs 48 aldosterone antagonist 48 HeFH 48 T1DM 48 postmenopausal osteoporotic women 48 elevated triglyceride levels 48 clinical trial 48 inflammatory biomarkers 48 Captopril 48 paroxetine Paxil 48 safety tolerability pharmacokinetic 48 randomized controlled Phase 48 Phase 2b trial 48 standard chemotherapy regimen 48 PreCISe study 48 HuMax EGFr 48 Multicenter Automatic Defibrillator Implantation 48 protease inhibitor PI 48 recurrent GBM 48 JAIDS 48 Unstable Angina 48 genotypic resistance 48 PLCO trial 48 HDL cholesterol triglycerides 48 quinacrine 47 Scandinavian Simvastatin Survival 47 ticagrelor 47 Clinical Efficacy 47 Glucosamine chondroitin Arthritis 47 longitudinal observational study 47 Phase 2a 47 relapsing multiple sclerosis 47 meta analysis pooling 47 Spine Patient Outcomes 47 insulin detemir 47 journal Lancet Neurology 47 Paroxysmal Nocturnal Hemoglobinuria 47 placebo controlled studies 47 Physiology Regulatory Integrative 47 IMPROVE HF 47 #:#-#,# [003] 47 Endarterectomy 47 ivabradine 47 Ischemic Stroke 47 cortical stimulation 47 tiotropium 47 LV dysfunction 47 Carotid Intima Media 47 ERSPC 47 dose dose escalation 47 agomelatine 47 prospectively defined 47 randomized controlled trial 47 safety tolerability pharmacokinetics 47 Placebo controlled 47 EuroIntervention 47 Clinical Oncology Annual Meeting 47 GFT# 47 EEG abnormalities 47 antiarrhythmic 47 thromboembolic complications 47 Avandia Actos 47 Torisel 47 Bivalirudin 47 RoACTEMRA 47 KRN# 47 AERAS-#/Crucell Ad# 47 #mg dosing group 47 Dabigatran 47 sulphonylureas 47 Cochrane Systematic Review 47 CC genotype 47 Study ADCS 47 Hemodialysis Patients 47 acute humoral rejection 47 hypertension 47 pomalidomide 47 Recurrent Stroke 47 bevacizumab Avastin 47 ST Elevation Myocardial 47 adiponectin concentrations 47 darunavir ritonavir 47 nonvertebral fractures 47 Acute Coronary Syndromes ACS 47 Phase IIb trial 47 atazanavir ritonavir 47 Clinical Psychopharmacology 47 assessing T DM1 47 CAPRISA 47 Thiazolidinediones 47 retrospective observational study 47 Phase III randomized placebo 47 Postmenopausal Women 47 relapsing remitting MS RRMS 47 icatibant 47 intensive statin therapy 47 underwent CABG 47 subgroup analyzes 47 Histopathological 47 IPAH 47 idraparinux 47 Dietary Modification Trial 47 Inflammatory Markers 47 Dual Antiplatelet Therapy 47 CYPHER R stent 47 Hypercholesterolemia 47 randomized #:#:# 47 pioglitazone 47 lipid profiles 47 NYHA Class II 47 glucocorticoid induced osteoporosis 47 ADMIRE HF 47 dyskinesia PD LID 47 NMIBC 47 analgesic efficacy 47 fenretinide 47 PON1 activity 47 fasting glucose levels 47 Subgroup analyzes 47 Resistant Hypertension 47 oral diclofenac 47 journal Anesthesia 47 Cancer Incidence Mortality 47 risperidone olanzapine 47 patients undergoing percutaneous 47 Heart Failure Patients 47 nondiabetic 47 Diabetes Mellitus 47 Decompensated Heart Failure 47 IDH1 mutation 47 macrovascular 47 Alpha Tocopherol Beta Carotene 47 serum lipids 47 peginterferon alfa 2b 47 blind randomized 47 systolic hypertension 47 Glucosamine Chondroitin Arthritis 47 Systematic Review 47 placebo controlled 47 prospective longitudinal 47 Phase III 47 Phase IIA 47 Metabolic Efficiency 47 #:# randomization 47 double blind placebo 47 CYPHER ® Stent 47 preserved ejection fraction 47 Late Breaker 47 FOSRENOL R 47 pretransplant 47 Clinical Practice Guideline 47 Rhinology 47 genotype 1a 47 Protelos 47 mixed dyslipidemia 47 null responder 47 carotid intima media 47 MADIT 47 symptomatic VTE 47 Wadih Arap 47 HbA1c levels 47 Radiation Therapy Oncology 47 Kari Hemminki 47 left ventricular hypertrophy 47 RESOLUTE clinical 47 ImmuKnow assay 47 events SAEs 47 Antimicrobial Chemotherapy 47 cardiovascular mortality 47 Primary endpoints 47 Doxil ® 47 antiretroviral naive 47 angiotensin II receptor blockers 47 journal Diabetologia 47 Metabolic Disease 46 Cohort Study 46 Prehypertension 46 Phase IIb 46 multiple ascending dose 46 ELCAP 46 EORTC 46 diabetes mellitus 46 CHAMPION PLATFORM 46 CALGB # [001] 46 postoperative atrial fibrillation 46 acute myocardial infarction MI 46 APTIVUS r 46 DCCT EDIC 46 paclitaxel eluting stents 46 strontium ranelate 46 ABC/3TC 46 randomized controlled trials RCTs 46 #:#-# [007] 46 Cardiovascular Risk Factors 46 Hypertension 46 radiographic outcomes 46 genomewide association studies 46 Phase III clinical 46 symptomatic BPH 46 chlorthalidone 46 Percutaneous Tibial Nerve Stimulation 46 CYP#D# inhibitor 46 Anticoagulant 46 hyperlipidemia hypertension 46 N. Engl 46 VFEND 46 EMPOWER ™ 46 infliximab Remicade 46 secretin 46 silent ischemia 46 Atypical Hemolytic Uremic Syndrome 46 Group RTOG 46 Nonalcoholic Fatty Liver Disease 46 lipid levels 46 MVA MUC1 IL2 46 HF ACTION 46 Hypotension 46 Chronic Myeloid Leukemia 46 blinded randomized 46 Stenting Trial 46 antihypertensive 46 Study ARIC 46 tamsulosin 46 MIST II 46 UA NSTEMI 46 Neovascular Age Related Macular 46 adenoma recurrence 46 FAME Study 46 newer antipsychotics 46 SCIg 46 SWOG 46 bendamustine 46 retrospectively analyzed 46 hypertensives 46 atherothrombotic disease 46 Dose escalation 46 carotid atherosclerosis 46 nab paclitaxel 46 ABCSG 46 resected pancreatic cancer 46 relapsing remitting multiple sclerosis 46 serum selenium 46 dose escalation study 46 Myelodysplastic Syndrome 46 RESIST studies 46 #:#-# [023] 46 ID NCT# 46 induce orthostatic hypotension 46 acute mania 46 Antiviral Therapy 46 Complications Trial DCCT 46 Endothelial Function 46 rapid virologic response 46 PREZISTA r 46 journal Atherosclerosis 46 sirolimus eluting stents 46 GAMMAGARD 46 Insulin Resistance 46 TAXUS ARRIVE 46 postmenopausal hormone therapy 46 Elocalcitol 46 label multicenter Phase 46 hematopoietic cancers 46 REYATAZ r arm 46 ovariectomized 46 peptic ulcer bleeding 46 angiotensin receptor blockers 46 Severe Asthma 46 ziprasidone 46 Nephrology Renal Week 46 Phase III randomized controlled 46 WTCCC 46 ascending dose study 46 interferon ribavirin 46 asymptomatic metastatic 46 unstable angina UA 46 CTEPH 46 Arch Intern Med 46 atherosclerotic renal artery stenosis 46 plasma pharmacokinetics 46 Cardiovascular Intervention 46 Slone Epidemiology Center 46 Periodontology JOP 46 carotid artery stenting CAS 46 Randomized Controlled Trials 46 Clinical Therapeutics 46 coronary revascularization 46 type2 diabetes 46 APOE genotype 46 placebo controlled trials 46 prospective observational studies 46 Ischemic 46 tipranavir r 46 nabilone 46 Chicago Multidisciplinary Symposium 46 Impaired Glucose Tolerance 46 arterial thromboembolic events 46 dosing cohorts 46 intravenous bisphosphonates 46 Multivariate analyzes 46 XELOX 46 undetectable HBV DNA 46 pharmacodynamic profile 46 onset AF 46 nonfasting triglycerides 46 eculizumab therapy 46 multivariate Cox 46 J Clin Endocrinol Metab 46 Phytotherapy Research 46 Chronic Bronchitis 46 Sequenced Treatment Alternatives 46 CCCEH 46 Diabetic Medicine 46 colorectal adenoma 46 resistant hypertension 46 neoadjuvant treatment 46 HbA 1c 46 Acute myocardial infarction 46 genetic polymorphisms 46 serum GGT 46 persistent pulmonary hypertension 46 postoperative mortality 46 randomized controlled trials 46 ENDEAVOR clinical 46 journal Molecular Psychiatry 46 antithrombotic therapies 46 diabetic kidney 46 CaPSURE 46 SNP rs# [002] 45 intracranial stenosis 45 dose cohorts 45 IDDM 45 melphalan prednisone 45 lowering LDL cholesterol 45 acute coronary syndromes 45 Knee Osteoarthritis 45 micafungin 45 BMC Musculoskeletal Disorders 45 logistic regression analysis 45 Univariate analysis 45 non fasting triglycerides 45 Ridker 45 mg administered orally 45 NYHA functional class 45 glycated hemoglobin levels 45 retrospective observational 45 bosentan 45 virologic failure 45 carotid endarterectomy CEA 45 abacavir lamivudine 45 RRMS patients 45 Poorly Controlled